enEnglisch
GD2IL18CART
A phase I safety, dose finding and feasibility trial of GD2IL18CART in patients with relapsed or refractory GD2 positive solid cancers
A phase I safety, dose finding and feasibility trial of GD2IL18CART in patients with relapsed or refractory GD2 positive solid cancers
Recruiting
Summary
For CAR-T-cell therapy, T cells from individual patients are genetically modified to selectively recognize and destroy tumor cells.
Children for whom standard therapies have failed and whose disease is considered incurable can be included after confirmation of sufficient GD2 expression in tumor biopsies.
Main inclusion criteria
- Age ≥1 and <80 years
- Diagnosis of relapsed and/or refractory (r/r) neuroblastoma, Ewing sarcoma or osteosarcoma, judged to be incurable with conventional treatment
- GD2 expression on tumor cells in archival or newly obtained biopsy
- ECOG 0-2 if >16 years
- Lansky >=60 if ≤16 years old at screening
Sponsor
Westfaelische Wilhelms Universität Münster